agilon health (AGL) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
18 Feb, 2026Executive summary
A special meeting of stockholders will be held virtually on March 17, 2026, to vote on two key proposals.
The main proposal is to approve an amendment authorizing a reverse stock split at a ratio between one-for-five and one-for-twenty-five, with the exact ratio to be determined by the board.
The reverse stock split aims to increase the per-share price to maintain NYSE listing compliance and improve marketability.
The board also seeks approval to adjourn the meeting if more time is needed to solicit votes for the amendment.
Proxy materials and annual reports are available online, and shareholders are encouraged to vote by internet, phone, or mail.
Voting matters and shareholder proposals
Proposal 1: Approve an amendment to effect a reverse stock split within a specified ratio range, without reducing authorized shares.
Proposal 2: Approve adjournment of the meeting if necessary to solicit additional votes for the amendment.
Both proposals are considered routine, allowing brokers discretionary voting if no instructions are given.
The board unanimously recommends voting FOR both proposals.
Board of directors and corporate governance
The board retains discretion to determine the timing and ratio of the reverse stock split or to abandon it entirely.
The board may consider market trends, stock price, and company performance in its decision.
No director or executive officer has a substantial interest in the reverse stock split beyond their share ownership.
Latest events from agilon health
- Profitability surged in Q1 2026, prompting raised full-year guidance and strong liquidity.AGL
Q1 20267 May 2026 - Tim O'Rourke named CEO and Director with new compensation terms; no changes to voting matters.AGL
Proxy filing27 Apr 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay, with board support.AGL
Proxy filing23 Apr 2026 - Proxy covers director elections, auditor ratification, pay-for-performance, and ESG priorities.AGL
Proxy filing23 Apr 2026 - 2026 guidance targets breakeven EBITDA and $5.5B revenue after cost discipline and transformation.AGL
Q4 20257 Apr 2026 - Shareholders approved a reverse stock split and adjournment proposal, both backed by the Board.AGL
EGM 202617 Mar 2026 - Transformation, data-driven care, and disciplined contracting set the stage for growth and stability.AGL
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - Disciplined contracting, cost controls, and clinical programs drive margin gains amid elevated trends.AGL
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Stockholders to vote on a reverse stock split, reducing shares to as low as 16.6 million.AGL
Proxy Filing20 Feb 2026